• Publications
  • Influence
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
BACKGROUND Parathyroid hormone increases bone strength primarily by stimulating bone formation, whereas antiresorptive drugs reduce bone resorption. We conducted a randomized, double-blind clinicalExpand
  • 1,043
  • 45
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit perspective. Two trials provided evidenceExpand
  • 308
  • 20
Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Context Researchers have not previously reported the efficacy and safety of parathyroid hormone (1-84) (PTH) for the primary prevention of osteoporotic fractures. Contributions Among 2532Expand
  • 324
  • 19
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
CONTEXT Although androgen deprivation therapy (ADT) for prostate cancer is associated with bone loss, little is known about when this bone loss occurs. OBJECTIVE We postulated that men on ADT wouldExpand
  • 317
  • 18
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.
1. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. Bilezikian JP, Khan AA, Potts JT Jr; Third InternationalExpand
  • 319
  • 17
Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass.
Little is known about the effects on the skeleton of laparoscopic Roux-en-Y gastric bypass (LRGB) surgery for morbid obesity and subsequent weight loss. We compared 25 patients who had undergone LRGBExpand
  • 376
  • 16
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
When used to treat osteoporosis, no more than 2 years of parathyroid hormone (PTH) is permitted, raising the question of whether antiresorptive therapy should be given after PTH is discontinued. ThisExpand
  • 144
  • 16
Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly.
OBJECTIVE To determine the relative importance of fall characteristics, body habitus, and femoral bone mineral density (BMD) in predicting hip fracture in community-dwelling elderly. DESIGNExpand
  • 513
  • 14
Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging.
PURPOSE To determine the clinical utility of gadolinium-enhanced fluid-attenuated inversion-recovery (FLAIR) magnetic resonance (MR) imaging of the brain by comparing results with those atExpand
  • 165
  • 14
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
BACKGROUND Since the use of parathyroid hormone as a treatment for osteoporosis is limited to two years or less, the question of whether antiresorptive therapy should follow parathyroid hormoneExpand
  • 373
  • 11